Search clinical trials for: gemcitabin

Total 2807 results

Hoffmann-La Roche

Active, not recruiting

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, France, Israel, Taiwan, Australia, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7 | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Bladder Cancer

United States
Seoul National University Hospital

Completed

Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 (HN17-11)

Recurrent or Metastatic Nasopharyngeal Carcinom

Korea, Republic of
BeiGene

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent or Metastatic Nasopharyngeal Cancer

China, Taiwan, Thailand
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Completed

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
Eli Lilly and Company

Active, not recruiting

A Study of LY3200882 in Participants With Solid Tumors

Solid Tumor

United States, Spain, Japan, France, Italy, Australia, Germany, Canada
Sun Yat-sen University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma (PLATINUM)

Nasopharyngeal Carcinoma

China
Hoffmann-La Roche

Active, not recruiting

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

Triple Negative Breast Neoplasms

Korea, Republic of, Italy, China, Finland, France, Hungary, Spain, United Kingdom, Argentina, United States, Bosnia and Herzegovina, Brazil, Chile, Germany, Poland, Russian Federation, Morocco, Mexico, Portugal, Serbia, Turkey, South... and more
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Suspended

Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Soft Tissue Sarcoma

United States
Ipsen

Active, not recruiting

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

Metastatic Adenocarcinoma of the Pancreas

United States, Spain, Hungary, France, Portugal, Korea, Republic of, Germany, United Kingdom, Austria, Italy, Israel, Australia, Brazil, Czechia, Belgium, Russian Federation, Canada, Greece
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
Baylor College of Medicine

Active, not recruiting

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer (BLAST)

Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Transitional Cell Carcinoma | Metastatic Urothelial Carcinoma | Unresectable Transitional Cell Carcinoma

United States
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Metastatic Cancer | Advanced Cancer | Biliary Tract Cancer

United States, Belgium, Spain, Australia, Czechia, Denmark, Korea, Republic of, Taiwan, Germany, Turkey, France, United Kingdom, Austria, Russian Federation, Mexico, Hungary, Argentina, Sweden
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States, Korea, Republic of, Japan, China, France, Turkey, Italy, Australia, Brazil, Ireland, Mexico, Spain, Taiwan
Herlev Hospital

Active, not recruiting

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. (LAPTOP)

Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer

Denmark
Hoffmann-La Roche

Active, not recruiting

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

United States, Spain, Italy, Taiwan, Belgium, China, Hong Kong, Japan, Germany, Canada, Israel, Russian Federation, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Ukraine, Romania, Australia, Hungary, Portugal
British Columbia Cancer Agency
Canadian Cancer Society (CCS); SignalChem Lifesciences Corporation

Terminated

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)

Metastatic Pancreatic Ductal Adenocarcinoma

Canada
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial Carcinoma

United States
Gilead Sciences
The Leukemia and Lymphoma Society

Terminated

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Non Hodgkin Lymphoma

United States, Australia, United Kingdom
AstraZeneca

Active, not recruiting

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

Non-Small Cell Lung Cancer

Belgium, Italy, Spain, United States, Poland, India, Taiwan, Thailand, Vietnam, Canada, France, Germany, Korea, Republic of, Brazil, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation, China, Austria, Chile, Netherlands, Bulg... and more
Indiana University
Purdue University

Terminated

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides (BDI)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Urinary Bladder Neoplasms

United States, Japan, China, Korea, Republic of, France, Belgium, Czechia, Taiwan, Italy, Poland, United Kingdom, Spain, Germany, Australia, Brazil, Argentina, India
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
Institut de Recherches Internationales Servier

Terminated

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Lymphoma | Advanced Solid Tumors

United States, Spain, France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Bladder Cancer | Urethral Cancer | Urachal Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Stage III Liver Cancer | Stage IV Liver Cancer

United States
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1)

Metastatic Pancreatic Ductal Adenocarcinoma

Belgium, Finland, Taiwan, Australia, Germany, Spain, Italy, Austria, Czechia, Switzerland, Singapore, United Kingdom, United States, France
Matthew Galsky
Bristol-Myers Squibb; Hoosier Cancer Research Network

Completed

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States
National Cancer Institute (NCI)

Completed

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Urethral Neoplasms | Urethral Cancer | Neoplasms, Urethral | Cancer of the Urethra

United States
Lyudmyla Berim

Active, not recruiting

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8

United States, Canada
AstraZeneca

Active, not recruiting

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

Biliary Tract Neoplasms

France, Italy, United States, Thailand, Korea, Republic of, United Kingdom, India, Japan, Poland, Russian Federation, Turkey, China, Taiwan, Hong Kong, Chile, Bulgaria, Argentina
Altor BioScience
National Cancer Institute (NCI)

Completed

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Pancreatic Adenocarcinoma

United States, Spain, Korea, Republic of, Germany, Japan
Mirati Therapeutics Inc.
Aadi Bioscience, Inc.

Active, not recruiting

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NSCLC | Metastatic Cancer | Advanced Cancer | Solid Tumor, Adult | Malignant Neoplastic Disease

United States
University of Birmingham
University of Oslo; The Leeds Teaching Hospitals NHS Trust; University of Padova and other collaborators

Active, not recruiting

Paediatric Hepatic International Tumour Trial (PHITT)

Carcinoma, Hepatocellular | Hepatoblastoma

United Kingdom, France, Austria, Israel, Spain, Belgium, Czechia, Finland, Germany, Ireland, Netherlands, Norway, Poland, Switzerland
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. (PAAG)

Pancreatic Neoplasms

China
University of Alabama at Birmingham

Terminated

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC)

Cholangiocarcinoma

United States
North Eastern German Society of Gynaecological...
Novartis Pharmaceuticals; medac GmbH

Active, not recruiting

Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble)

Leiomyosarcoma or Carcinosarcoma

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma

United States
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Sanofi

Active, not recruiting

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01)

Breast Cancer Metastatic | Pancreatic Carcinoma Metastatic

Spain, Korea, Republic of, Turkey, Chile, Netherlands, Russian Federation, Taiwan, United States, Argentina, Hungary
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States

Search clinical trials for: gemcitabin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations